Semaglutide comes out on top in GLP1RA CVD comparison

  • Alfayez OM & al.
  • Cardiovasc Diabetol
  • 22 Jun 2020

  • curated by Miriam Tucker
  • Clinical Essentials
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Glucagon-like peptide-1 receptor agonists (GLP1RAs) offer significant cardiovascular (CV) safety benefits, according to an analysis of data from CV outcomes trials.
  • An indirect comparison across trials suggests once-weekly semaglutide and oral semaglutide may be preferred GLP1RAs in patients with type 2 diabetes (T2D) with established or at high risk for CV disease (CVD).

Why this matters

  • No head-to-head trials compare CV outcomes among different GLP1RAs.

Study design

  • Indirect comparison of data from 7 GLP1RA CV outcomes trials, including 56,004 patients with T2D and established CVD or risk factors.
  • Funding: King Saud University, Riyadh, Saudi Arabia.

Key results

  • With weekly injected semaglutide vs lixisenatide, significant reductions seen in major adverse cardiovascular events (MACE): OR, 0.71 (95% CI, 0.52-0.96).
  • MACE risk reductions also seen with albiglutide vs lixisenatide: OR, 0.76 (95% CI, 0.61-0.93).
  • Weekly semaglutide had highest probability of ranking first in MACE reduction (52%) followed by oral semaglutide (26%) and albiglutide (20%).
  • CV mortality (ORs; 95% CIs) was significantly reduced with:
    • Semaglutide vs exenatide: 0.47 (0.21-0.99).
    • Semaglutide vs dulaglutide: 0.46 (0.20-0.97).
    • Semaglutide vs albiglutide: 0.45 (0.19-0.97). 
    • Semaglutide vs lixisenatide: 0.43 (0.19-0.92).
  • Semaglutide also had the highest probability of ranking first (>90%) in CV mortality reduction.

Limitations

  • Intertrial differences in study populations, MACE component results.
  • Albiglutide is no longer available.
  • Other decision-making parameters, such as cost, weight reduction, and glycemic control not addressed.